Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Induction of the inflammasome pathway by tyrosine kinase inhibitors provides an actionable therapeutic target for hepatocellular carcinoma

  • Tutusaus, Anna
  • Sanduzzi Zamparelli, Marco
  • Boix, Loreto
  • Rider, Patricia
  • Subías, Silvia
  • García de Frutos, Pablo
  • Colell, Anna
  • Marí, Montserrat
  • Reig, María
  • Morales, Albert
During the last decade, tyrosine kinase inhibitors (TKIs) sorafenib and regorafenib have been standard systemic treatments for advanced hepatocellular carcinoma (HCC). Previous data associated sorafenib with inflammasome activation. However, the role of the inflammasome in sorafenib and regorafenib signaling has not been described in liver cancer patients. For this purpose, we analyzed inflammasome-related transcriptomic changes in a murine HCC model. Our data confirmed inflammasome activation after both TKI treatments, sharing a similar pattern of increased gene expression. According to human database results, transcriptional increase of inflammasome genes is associated with poorer prognosis for male liver cancer patients, suggesting a sex-dependent role for inflammasome activation in HCC therapy. In biopsies of HCC and its surrounding tissue, we detected durable increases in the inflammasome activation pattern after sorafenib or regorafenib treatment in male patients. Further supporting its involvement in sorafenib action, inflammasome inhibition (MCC950) enhanced sorafenib anticancer activity in experimental HCC models, while no direct in vitro effect was observed in HCC cell lines. Moreover, activated human THP-1 macrophages released IL-1β after sorafenib administration, while 3D Hep3B spheres displayed increased tumor growth after IL-1β addition, pointing to the liver microenvironment as a key player in inflammasome action. In summary, our results unveil the inflammasome pathway as an actionable target in sorafenib or regorafenib therapy and associate an inflammasome signature in HCC and surrounding tissue with TKI administration. Therefore, targeting inflammasome activation, principally in male patients, could help to overcome sorafenib or regorafenib resistance and enhance the efficacy of TKI treatments in HCC., This research was funded by Instituto de Salud Carlos III (ISCIII) through project PI22/00475 to M.M., FI19/00222 to M.S.-Z. and PI18/0358 to M.R., and co-funded by the European Union “ERDF A way of making Europe”; CIBEREHD, CIBERCV, and CIBERNED; Ministerio de Ciencia, Innovación y Universidades: grant numbers PID2021-123564OB-I00 and PDC2023-145806-I00 to A.M/P.G.F. and PID2022-143279OB-I00 to A.C. funded by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe”. AGAUR, grant number 2021_SGR_00490 to A.C.; Fundació la Marató de TV3 to A.M.; and CERCA Programme/Generalitat de Catalunya.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Induction of the Inflammasome Pathway by Tyrosine Kinase Inhibitors Provides an Actionable Therapeutic Target for Hepatocellular Carcinoma

  • Tutusaus, Anna
  • Sanduzzi-Zamparelli, Marco
  • Boix, Loreto
  • Rider, Patricia
  • Subías, Silvia
  • García de Frutos, Pablo
  • Colell Riera, Anna
  • Marí, Montserrat
  • Reig, Maria
  • Morales, Albert
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/)., Simple Summary: In the past decade, tyrosine kinase inhibitors sorafenib and regorafenib have been standard treatments for advanced liver cancer. Previous studies have associated sorafenib with inflammasome activation, but its therapeutic role in patients has not been explored. Our study found that both treatments altered inflammasome-related gene expression, showing a similar transcriptomic pattern in a mouse model of liver cancer. In accordance with public databases, inflammasome genes are associated with a poorer prognosis in male liver cancer patients, without changes in females. Thus, we analyzed biopsies from hepatocellular carcinoma patients treated with sorafenib/regorafenib and confirmed inflammasome activation. In experimental models, inflammasome inhibition enhanced sorafenib effectiveness, demonstrating its potential to overcome therapy resistance and improve its efficacy for liver cancer treatment., Abstract: During the last decade, tyrosine kinase inhibitors (TKIs) sorafenib and regorafenib have been standard systemic treatments for advanced hepatocellular carcinoma (HCC). Previous data associated sorafenib with inflammasome activation. However, the role of the inflammasome in sorafenib and regorafenib signaling has not been described in liver cancer patients. For this purpose, we analyzed inflammasome-related transcriptomic changes in a murine HCC model. Our data confirmed inflammasome activation after both TKI treatments, sharing a similar pattern of increased gene expression. According to human database results, transcriptional increase of inflammasome genes is associated with poorer prognosis for male liver cancer patients, suggesting a sex-dependent role for inflammasome activation in HCC therapy. In biopsies of HCC and its surrounding tissue, we detected durable increases in the inflammasome activation pattern after sorafenib or regorafenib treatment in male patients. Further supporting its involvement in sorafenib action, inflammasome inhibition (MCC950) enhanced sorafenib anticancer activity in experimental HCC models, while no direct in vitro effect was observed in HCC cell lines. Moreover, activated human THP-1 macrophages released IL-1β after sorafenib administration, while 3D Hep3B spheres displayed increased tumor growth after IL-1β addition, pointing to the liver microenvironment as a key player in inflammasome action. In summary, our results unveil the inflammasome pathway as an actionable target in sorafenib or regorafenib therapy and associate an inflammasome signature in HCC and surrounding tissue with TKI administration. Therefore, targeting inflammasome activation, principally in male patients, could help to overcome sorafenib or regorafenib resistance and enhance the efficacy of TKI treatments in HCC., This research was funded by Instituto de Salud Carlos III (ISCIII) through project PI22/00475 to M.M., FI19/00222 to M.S.-Z. and PI18/0358 to M.R., and co-funded by the European Union “ERDF A way of making Europe”; CIBEREHD, CIBERCV, and CIBERNED; Ministerio de Ciencia, Innovación y Universidades: grant numbers PID2021-123564OB-I00 and PDC2023-145806-I00 to A.M/P.G.F. and PID2022-143279OB-I00 to A.C. funded by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe”. AGAUR, grant number 2021_SGR_00490 to A.C.; Fundació la Marató de TV3 to A.M.; and CERCA Programme/Generalitat de Catalunya., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Neuroinflammation in Age-Related Neurodegenerative Diseases: Role of Mitochondrial Oxidative Stress

  • Abadin, Xenia
  • Dios, Cristina de
  • Zubillaga, Marlene
  • Ivars, Elia
  • Puigros Serra, Margalida
  • Marí, Montserrat
  • Morales, Albert
  • Vizuete, Marisa
  • Vitorica, Javier
  • Trullas, Ramón
  • Colell Riera, Anna
  • Roca-Agujetas, Vicente
A shared hallmark of age-related neurodegenerative diseases is the chronic activation of innate immune cells, which actively contributes to the neurodegenerative process. In Alzheimer's disease, this inflammatory milieu exacerbates both amyloid and tau pathology. A similar abnormal inflammatory response has been reported in Parkinson's disease, with elevated levels of cytokines and other inflammatory intermediates derived from activated glial cells, which promote the progressive loss of nigral dopaminergic neurons. Understanding the causes that support this aberrant inflammatory response has become a topic of growing interest and research in neurodegeneration, with high translational potential. It has been postulated that the phenotypic shift of immune cells towards a proinflammatory state combined with the presence of immunogenic cell death fuels a vicious cycle in which mitochondrial dysfunction plays a central role. Mitochondria and mitochondria-generated reactive oxygen species are downstream effectors of different inflammatory signaling pathways, including inflammasomes. Dysfunctional mitochondria are also recognized as important producers of damage-associated molecular patterns, which can amplify the immune response. Here, we review the major findings highlighting the role of mitochondria as a checkpoint of neuroinflammation and immunogenic cell deaths in neurodegenerative diseases. The knowledge of these processes may help to find new druggable targets to modulate the inflammatory response., This research was funded by MCIN/AEI/10.13039/501100011033, co-funded by NextGenera-tionEU/PRTR, and by “ERDF A way of making Europe”, grants PID2022-143279OB-100 (A.C.), PID2021-123564OB-100 (A.M.), PDC2023-145806-100 (A.M and M.M.), PID2020-115091RB-I00 (R.T.), and RED2022-134786-T (A.C. and R.T.); Instituto de Salud Carlos III (ISCIII) and European Union NextGenerationEU/PRTR, grants PMP22/00100 (R.T. and A.C.) and PI22/00475 (M.M.); Fundació la Marató de TV3 (A.M.); AGAUR, grant 2021-SGR00490 (A.C.); and Junta de Andalucia (Consejería de Economia y Conocimiento) co-funded by FEDER 214-2020 and by the CIBERNED (Convocatoria 2022 Proyectos Colaborativos 2020/21), grants US-1262734 (J.V.) and P20-00843 (J.V.). V.R.-A. has a Juan de la Cierva postdoctoral contract (JDC2022-048952-I) funded by MCIN/AEI/10.13039/501100011033 and by NextGenerationEU/PRTR. C.D. has a contract (2022 INV-1 00065) funded by “Programa Investigo” MCIN/PRTR., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Lymphocyte exhaustion in hepatocellular carcinoma: a dynamic evolution across disease stages

  • Fuster-Anglada, Carla
  • Corominas, Josep
  • Marsal, Aida
  • Llarch, Neus
  • Iserte, Gemma
  • Sanduzzi-Zamparelli, Marco
  • Forner, Alejandro
  • Ferrer-Fábrega, Joana
  • Holguin, Víctor Emilio
  • Morales, Albert
  • Saavedra, Carolina
  • Reig, Maria
  • Boix, Loreto
  • Marí, Montserrat
  • Díaz, Alba
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy. However, their efficacy in hepatocellular carcinoma (HCC) is limited, highlighting the need to further explore immune microenvironments and novel biomarkers. This study examined lymphocyte populations and immune checkpoint dynamics in early, advanced, and post-progression HCC to better understand immune dynamics in HCC and to help identify predictive biomarkers and immune modulation strategies., The author(s) declare that financial support was received for the research and/or publication of this article. Premi final de residencia “Emili Letang-Josep Font” to CF-A. This research was funded by Instituto de Salud Carlos III (ISCIII) through projects PI22/01427 to MR, PI22/00475 to MM, MCIN/AEI/10.13039/501100011033, PID2021-123564OB-100 and PDC2023-145806–100 to AM, and co-funded by NextGenerationEU/PRTR, and by “ERDF A way of making Europe”; CIBEREHD; MSZ: received grant support from Instituto de Salud Carlos III (FI19/00222) and from CIBEREHD (CIBER/EHD25PI02)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Picrosirius red, polarized light microscopy, and curvelet transform analysis: An improved method for liver fibrosis assessment

  • Cuño-Gómiz, Carlos
  • Tutusaus, Anna
  • Savino, Flavia
  • Rider, Patricia
  • Colell, Anna
  • Morales, Albert
  • Marí, Montserrat
Liver fibrosis is a hallmark of chronic liver diseases, characterized by excessive extracellular matrix deposition and structural alterations. Conventional histological assessments rely on qualitative or semi-quantitative scoring systems that may lack sensitivity for subtle fibrotic changes. Here, we present an improved fibrosis evaluation method integrating Picrosirius Red (PSR) staining, polarized light (PL) microscopy, and curvelet transform-based fiber analysis (CT-FIRE). This approach provides a quantitative and reproducible assessment of collagen fiber morphology and composition. Applied to murine models of metabolic dysfunction-associated steatohepatitis (MASH)-induced fibrosis, our method reveals novel insights into fibrosis progression and strain-dependent variations. This enhanced workflow offers a cost-effective, high-resolution tool for fibrosis analysis in preclinical research., This research was funded by Instituto de Salud Carlos III (ISCIII) through project PI22/00475 to M.M., and co-funded by the European Union “ERDF A way of making Europe”; CIBEREHD; Ministerio de Ciencia, Innovación y Universidades: grant numbers PID2021–123564OB-I00 and PDC2023–145806-I00 to A.M, PID2022–143279OB-100 to A.C., funded by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe”. AGAUR, grant number 2021_SGR_00490., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Induction of the inflammasome pathway by tyrosine kinase inhibitors provides an actionable therapeutic target for hepatocellular carcinoma

  • Tutusaus, Anna
  • Sanduzzi Zamparelli, Marco
  • Boix, Loreto
  • Rider, Patricia
  • Subías, Silvia
  • García de Frutos, Pablo
  • Colell, Anna
  • Marí, Montserrat
  • Reig, María
  • Morales, Albert
During the last decade, tyrosine kinase inhibitors (TKIs) sorafenib and regorafenib have been standard systemic treatments for advanced hepatocellular carcinoma (HCC). Previous data associated sorafenib with inflammasome activation. However, the role of the inflammasome in sorafenib and regorafenib signaling has not been described in liver cancer patients. For this purpose, we analyzed inflammasome-related transcriptomic changes in a murine HCC model. Our data confirmed inflammasome activation after both TKI treatments, sharing a similar pattern of increased gene expression. According to human database results, transcriptional increase of inflammasome genes is associated with poorer prognosis for male liver cancer patients, suggesting a sex-dependent role for inflammasome activation in HCC therapy. In biopsies of HCC and its surrounding tissue, we detected durable increases in the inflammasome activation pattern after sorafenib or regorafenib treatment in male patients. Further supporting its involvement in sorafenib action, inflammasome inhibition (MCC950) enhanced sorafenib anticancer activity in experimental HCC models, while no direct in vitro effect was observed in HCC cell lines. Moreover, activated human THP-1 macrophages released IL-1β after sorafenib administration, while 3D Hep3B spheres displayed increased tumor growth after IL-1β addition, pointing to the liver microenvironment as a key player in inflammasome action. In summary, our results unveil the inflammasome pathway as an actionable target in sorafenib or regorafenib therapy and associate an inflammasome signature in HCC and surrounding tissue with TKI administration. Therefore, targeting inflammasome activation, principally in male patients, could help to overcome sorafenib or regorafenib resistance and enhance the efficacy of TKI treatments in HCC., This research was funded by Instituto de Salud Carlos III (ISCIII) through project PI22/00475 to M.M., FI19/00222 to M.S.-Z. and PI18/0358 to M.R., and co-funded by the European Union “ERDF A way of making Europe”; CIBEREHD, CIBERCV, and CIBERNED; Ministerio de Ciencia, Innovación y Universidades: grant numbers PID2021-123564OB-I00 and PDC2023-145806-I00 to A.M/P.G.F. and PID2022-143279OB-I00 to A.C. funded by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe”. AGAUR, grant number 2021_SGR_00490 to A.C.; Fundació la Marató de TV3 to A.M.; and CERCA Programme/Generalitat de Catalunya.